NASDAQ:UTHR

United Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Retrieved on: 
水曜日, 6月 5, 2024
Biotechnology, Surgery, Health, Pharmaceutical, Cardiology, United Therapeutics, Creativity, Conference, UTHR, PBC, Patient, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida.
  • An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
  • At United Therapeutics, our vision and mission are one.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024

Retrieved on: 
水曜日, 4月 24, 2024
Biotechnology, General Health, Health, Pharmaceutical, Cardiology, United Therapeutics, Webcast, Creativity, UTHR, PBC, Therapy, Patient

United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024.
  • A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
  • United Therapeutics will host a public webcast Wednesday, May 1, 2024, at 9:00 a.m. Eastern Time.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Announces World’s First Successful Xenothymokidney Transplant

Retrieved on: 
金曜日, 4月 26, 2024
Cardiology, Biotechnology, FDA, Other Health, Health, Pharmaceutical, Other Science, Research, Surgery, Science, Clinical Trials, University, Birmingham School of Law, Cell, Transplant, Food, Tissue, Human services, Heart, NYU Langone Health, Surgeon, History, Doctor of Philosophy, UTHR, Patient, Regenerative medicine, Multimedia, Creativity, Immune system, PBC, Therapy, Food and Drug Administration, Knowledge

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first successful transplant of a UThymoKidney™, which the company produced, into a living person on April 12, 2024.
  • (Photo: Business Wire)
    - The first-ever transplant of a xenothymokidney into a living human recipient;
    - The first-ever combined mechanical heart pump and organ transplant; and
    The transplant is the third xenotransplant using United Therapeutics’ xeno organs, following two successful UHeart™ transplants at the University of Maryland Medicine in 2022 and 2023.
  • United Therapeutics’ xenothymokidney, known by the proposed trade name UThymoKidney, is an investigational-stage xenokidney from a pig with a single genetic edit, together with tissue from the same pig’s thymus.
  • United Therapeutics is preparing for clinical trials of its xenokidney, xenothymokidney, and xenoheart products, following completion of ongoing preclinical studies required by the FDA.

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference

Retrieved on: 
火曜日, 4月 16, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Rationale, University, Idiopathic pulmonary fibrosis, ATSF, ATS, Pulmonary hypertension, Route of administration, High Risk, PAH, Conference, Research, Electronic health record, Idiopathic disease, Orthostatic hypertension, University of North Carolina, Intelligence, Data, Pulmonary fibrosis, UTHR, Treatment, Doctor of Pharmacy, Inova Fairfax Hospital, University of Lagos, Prevalence, University of Florida, Creativity, American Thoracic Society, Medicine, PBC, Therapy, Theme, Incident, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024.
  • At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the company is sponsoring the ATS 2024 Women’s Forum.
  • “We look forward to presenting the latest data on several of our key products and development programs,” said Andrew Nelsen, PharmD, Vice President, Global Medical Affairs at United Therapeutics.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Announces the First Comprehensive Review Publication on Xenotransplantation

Retrieved on: 
火曜日, 3月 26, 2024
Research, Clinical Trials, Cardiology, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, FRS, Gene editing, Acute liver failure, New product development, UTHR, Patient, United Therapeutics, Lung, Xenotransplantation, Manuscript, MBBS, Regenerative medicine, PBC, Clinical trial, Therapy, Heart, Creativity, Physiology, Kidney, FACS, FRCS, Liver, Physiological Reviews, Food, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological Reviews.
  • Beyond xenotransplantation, United Therapeutics has six other organ manufacturing programs in the lung, kidney, and liver using three distinct platforms: regenerative medicine, bio-artificial organs, and 3-D organ printing.
  • United Therapeutics believes that this study will be the first human clinical trial of a manufactured organ.
  • At United Therapeutics, our vision and mission are one.

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program

Retrieved on: 
月曜日, 3月 25, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, UTHR, Patient, ASR, PBC, Sale, Therapy, Creativity, Citibank, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock.
  • This program builds on United Therapeutics’ planned $400 million paydown of its revolving credit facility in 2024, of which $100 million was paid down during the first quarter of 2024.
  • To enact the program, United Therapeutics today will enter into an Accelerated Share Repurchase (ASR) agreement with Citibank, N.A.
  • At final settlement of the ASR agreement, United Therapeutics may be entitled to receive additional shares of United Therapeutics’ common stock, or, under certain limited circumstances, be required to make cash payment to Citi or, if United Therapeutics elects, deliver shares to Citi.

United Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
火曜日, 3月 5, 2024
Biotechnology, Pharmaceutical, Health, United Therapeutics, Patient, Creativity, UTHR, PBC, Conference

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.
  • The session will take place on Tuesday, March 12, 2024, from 1:40 p.m. to 2:10 p.m., Eastern Daylight Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations .
  • An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).

United Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care Conference

Retrieved on: 
火曜日, 2月 27, 2024
Health, Research, Pharmaceutical, Science, Cardiology, Biotechnology, United Therapeutics, Creativity, UTHR, PBC, Patient, Conference, Pharmaceutical industry

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.

Key Points: 
  • United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44th Annual Health Care Conference in Boston.
  • An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
  • At United Therapeutics, our vision and mission are one.
  • We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC).